Month: December 2020

L’ÉTUDE DE PHASE 2B/3 ÉVALUANT LE MASITINIB DANS LA MALADIE D’ALZHEIMER A ATTEINT SON OBJECTIF PRINCIPALLE MASITINIB A EU UN EFFET SIGNIFICATIF SUR LA COGNITION, MESURÉE AVEC L’ADAS-COG, ET SUR L’ACTIVITÉ QUOTIDIENNE, MESURÉE AVEC L’ADCS-ADLAB SCIENCE TIENDRA AVEC DIFFERENTS LEADERS D’OPINIONS UNE CONFERENCE VIRTUELLE LE 17 DECEMBRE 2020 – 17h-18h CET – SUR LES RESULTATS DE CETTE ETUDEParis, 16 décembre 2020, 8h00AB Science SA (Euronext – FR0010557264 – AB) annonce aujourd’hui que l’étude de phase 2B/3 (AB09004 – NCT01872598) évaluant le masitinib chez des patients atteints de la maladie d’Alzheimer, sous sa forme légère ou modérée, a atteint son critère d’évaluation principal prédéfini.L’étude AB09004 était une étude internationale de phase...

 Company AnnouncementCopenhagen, 16 December 2020No. 25/2020 Stronger. Simpler. Closer. ISS A/S (ISS.CO, ISS DC, ISSDY) today announces a refreshed strategy founded in our continued belief to fully play our part in creating a fair and inclusive society – caring for people and providing them with opportunities to develop into the best they can be. We believe people make places and places make people.By sharpening our focus on key segments, accelerating technology investments, and introducing a new globally aligned operating model, we will use our global scale to drive superior value for all stakeholders to become the most respected global leader in integrated facility services and strengthen our position as number one in cleaning.Our extensive business review confirms that the key account strategy and IFS business model remain attractive...

VALMIERAS STIKLA ŠĶIEDRA, AS (Registration No.: 40003031676, legal address: Cempu iela 13, Valmiera, LV-4201) informs that in 2021 submission of financial results is scheduled for the following dates:audited separate and consolidated financial statements of 2020 – on 30 April 2021;unaudited consolidated financial information of a 3-month period during 2021 – on 31 May 2021;unaudited consolidated financial statement of a 6-month period during 2021 – on 31 August 2021;unaudited consolidated financial information of a 9-month period during 2021 – on 30 November 2021.Additional information:AS VALMIERAS STIKLA ŠĶIEDRATel.: +371 64202216E-mail: latvia@valmiera-glass.comwww.valmiera-glass.com

AS VALMIERAS STIKLA ŠĶIEDRA (reģistrācijas Nr.: 40003031676, juridiskā adrese: Cempu ielā 13, Valmierā, LV-4201) informē, ka 2021. gadā finanšu rezultātu iesniegšana plānota šādos datumos:auditēts 2020. gada atsevišķais un konsolidētais finanšu pārskats – 2021. gada 30. aprīlī;neauditēta 2021. gada 3 mēnešu konsolidēta finanšu informācija – 2021. gada 31. maijā;neauditēts 2021. gada 6 mēnešu konsolidētais finanšu pārskats – 2021. gada 31. augustā;neauditēta 2021. gada 9 mēnešu konsolidēta finanšu informācija – 2021. gada 30. novembrī.Papildu informācija:AS VALMIERAS STIKLA ŠĶIEDRATālr.: +371 6420 2216E-pasts: latvia@valmiera-glass.comwww.valmiera-glass.com

Saint-Herblain (France), December 16, 2020 – Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.VLA2001 leverages the manufacturing platform of Valneva’s licensed Japanese encephalitis vaccine, IXIARO® and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe.The VLA2001-201 study is a randomized, double blind and placebo-controlled trial evaluating the safety and immunogenicity for three dose levels in approximately 150 healthy adults.The study will be conducted in study sites across the United Kingdom and is supported by the National Institute for Health Research (NIHR).The primary endpoint read-out...

 Saint-Herblain (France), 16 décembre 2020 – Valneva SE (“Valneva”), société spécialisée dans les vaccins contre des maladies générant d’importants besoins médicaux, a annoncé aujourd’hui l’initiation d’une étude clinique de Phase 1/2 pour son candidat vaccin inactivé et adjuvanté contre le COVID-19, VLA2001.VLA2001 est produit sur la plateforme de production que Valneva utilise pour son vaccin IXIARO®, autorisé pour une immunisation contre l’encéphalite japonaise, et est actuellement le premier vaccin inactivé contre la COVID-19 annoncé comme entrant en développement clinique en Europe.L’étude VLA2001-201 est une étude randomisée, à double aveugle, contrôlée par placebo, évaluant l’innocuité et l’immunogénicité de trois différentes doses du vaccin chez environ 150 adultes sains.L’étude sera menée sur des sites au Royaume-Uni et est soutenue...

Oslo, 16 December 2020Reference is made to the announcement by Thin Film Electronics ASA (the “Company”) on 20 May 2020 regarding an Extraordinary General Meeting where the shareholders resolved to issue warrants to participants in a Private Placement and Subsequent Offering of shares, and to the announcement on 30 November 2020 regarding the latest round of warrant exercises.Following this warrant exercise, 75.17% of the total issued Warrants A have been exercised.The deadline for exercising Warrants A is 31 December 2020. Any unexercised Warrants A will have no value after 31 December 2020 and will expire without compensation to the holder.Notice to exercise Warrants A must be received by the Company within and no later than 31 December 2020 to be eligible for exercise.Information regarding the procedure for exercise of...

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SOGosselies, Belgium, 16 December 2020, 7am CET – BONE THERAPEUTICS SA (Euronext Brussels and Paris: BOTHE; or “Bone Therapeutics”), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces the closing of the previously announced private placement with investors having purchased 4,408,881 new shares at an issue price of EUR 2.25 per share resulting in gross proceeds of approximately EUR 10 million (the “Private Placement“). With the total gross proceeds raised through the Private Placement, Bone Therapeutics anticipates having sufficient cash to carry out...

LE PRÉSENT COMMUNIQUÉ NE DOIT PAS ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, TOTALEMENT OU PARTIELLEMENT, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS, EN AUSTRALIE, AU CANADA, AU JAPON, EN AFRIQUE DU SUD, OU DANS TOUT AUTRE JURIDICTION INTERDISANT DE TELLES PRATIQUESGosselies, Belgique, le 16 décembre 2020 à 7h00 CET – BONE THERAPEUTICS SA (Euronext Bruxelles et Paris : BOTHE ; ou « Bone Therapeutics »), société de biotechnologie spécialisée dans le développement de thérapies cellulaires innovantes répondant aux besoins médicaux non satisfaits en orthopédie et dans d’autres pathologies graves, annonce aujourd’hui la clôture du Placement Privé annoncé le 11 décembre 2020, après l’achat par les investisseurs de 4 408 881 nouvelles actions au prix d’émission de 2,25 euros par action pour un produit brut d’environ 10 millions d’euros (le « Placement...

Nokia CorporationStock Exchange ReleaseDecember 16, 2020, at 08:00 (CET +1)Nokia provides a mid-point update on strategy and operating modelNokia aligns to deliver critical networks to CSPs, enterprises and webscales.Company aims for technology leadership in all segments it chooses to play in.Nokia sees value gradually migrating from monolithic systems towards silicon, cloud-native software and services, and the industry moving towards as-a-service business models.Provides transparency on expected operating margin performance of its four new business groups in 2021. Previously provided outlook for 2020 and 2021 remain unchanged.Espoo, Finland – Today Nokia provides an update on its strategy and operating model. On October 29 Nokia announced the first phase of its new strategy, outlining high-level strategic principles alongside a new...